Immunologic Biomarker Findings for mFOLFOX6 and Pembrolizumab in CRC

Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses immunologic biomarker findings in a study of mFOLFOX6 plus pembrolizumab (Keytruda) in colorectal cancer.